ELAVL3 and amyotrophic lateral sclerosis: These results were recently shown in detail in an experimental study reporting uniform downregulation of ELAVL3 in extensive ALS iPSC-MNs models at both RNA and protein levels and, importantly, this decrease was present beginning in early development, suggesting that ELAVL3 is an early modulator of downstream disease [21].